33 episodes

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerVoice Brain & Behaviour Audio PeerVoice

    • Science

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    The Fear of Disappearing, the Fight to Stay Present': Understanding the Needs of Patients With Alzheimer's Disease

    The Fear of Disappearing, the Fight to Stay Present': Understanding the Needs of Patients With Alzheimer's Disease

    Visit https://www.peervoice.com/VDJ860 to view the entire programme with slides. After completing “The Fear of Disappearing, the Fight to Stay Present': Understanding the Needs of Patients With Alzheimer's Disease”, participants will be able to: Describe how a diagnosis of Alzheimer's disease (AD) can impact patients and hence the importance of patient collaboration and communication; and Identify practical approaches to shared decision-making between expert and patients with AD during treatment planning.

    • 15 min
    Managing Long-Chain Fatty Acid Disorders: Experience of Novel Therapies in the Real World

    Managing Long-Chain Fatty Acid Disorders: Experience of Novel Therapies in the Real World

    Visit https://www.peervoice.com/TAW860 to view the entire programme with slides. After completing “Managing Long-Chain Fatty Acid Disorders: Experience of Novel Therapies in the Real World”, participants will be able to: Describe the recent developments in the management of long-chain fatty acid oxidation disorders (LC-FAOD); Identify the patient characteristics and disease manifestations that would indicate a need to initiate a novel therapeutic approach to managing LC-FAOD; and Formulate practical approaches to optimise the management of patients with LC-FAOD on a novel therapy.

    • 24 min
    Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics

    Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics

    Visit https://www.peervoice.com/TMJ860 to view the entire programme with slides. After completing “Perspectives in Acute Hepatic Porphyria Care: Improving Long-Term Management with Novel Therapeutics”, participants will be able to: Summarise key findings from the 24-month analysis of the ENVISION trial in patients with acute hepatic porphyria (AHP); Discuss the current practices and unmet needs for the long-term management of AHP; and Describe the impact of these data on clinical practice within the context of treatment paradigms for the long-term management of patients with AHP.

    • 32 min
    Proactive Stroke Risk Mitigation Strategies: Taking Aim in Type 2 Diabetes

    Proactive Stroke Risk Mitigation Strategies: Taking Aim in Type 2 Diabetes

    Visit https://www.peervoice.com/ANV860 to view the entire programme with slides. After completing “Proactive Stroke Risk Mitigation Strategies: Taking Aim in Type 2 Diabetes”, participants will be able to: Recognise the impact of type 2 diabetes (T2DM) on stroke risk; Differentiate between the patterns and characteristics of stroke in people with T2DM compared to those without; and Apply practical strategies for managing stroke risk in patients with T2DM.

    • 40 min
    Treatment Goals in Systemic Lupus Erythematosus: How Are We Raising the Bar?

    Treatment Goals in Systemic Lupus Erythematosus: How Are We Raising the Bar?

    Visit https://www.peervoice.com/HVF860 to view the entire programme with slides. After completing “Treatment Goals in Systemic Lupus Erythematosus: How Are We Raising the Bar?”, participants will be able to: Summarise the potential consequences of not achieving disease control in patients with systemic lupus erythematosus (SLE); Discuss the latest clinical guidelines for the therapeutic management of patients with moderate-to-severe SLE in the context of achieving the goals aligned with clinical remission; and Propose opportunities to optimise management of patients with moderate-to-severe SLE using treatment strategies geared towards prevention of long-term organ damage.

    • 45 min
    Stroke Prevention in T2DM: The Neuroprotective Benefits of GLP-1 RAs

    Stroke Prevention in T2DM: The Neuroprotective Benefits of GLP-1 RAs

    Visit https://www.peervoice.com/QGT860 to view the entire programme with slides. After completing “Stroke Prevention in T2DM: The Neuroprotective Benefits of GLP-1 RAs”, participants will be able to: Discuss the burden of stroke in patients with type 2 diabetes mellitus (T2DM) and recognise features of stroke in patients at risk; Analyse the safety and efficacy of GLP-1 receptor agonists (RAs) for the prevention of stroke in patients with T2DM; and Translate current guideline recommendations for stroke prevention in patients with T2DM into practical management plans.

    • 33 min

Top Podcasts In Science

Hidden Brain
Alie Ward
Neil deGrasse Tyson
Sam Harris
Vox
PRX and Greater Good Science Center

More by PeerVoice

PeerVoice
PeerVoice
PeerVoice
PeerVoice
PeerVoice
PeerVoice